Topics

Allogene pens $309mm deal with Notch, gaining equity stake and global rights to allogenic therapies for hematologic cancers

14:40 EST 8 Nov 2019 | Elsevier Business Intelligence

Allogene Therapeutics Inc. and Notch Therapeutics (a 2018 start-up) agreed to jointly R&D induced pluripotent stem cell (iPSC...

Original Article: Allogene pens $309mm deal with Notch, gaining equity stake and global rights to allogenic therapies for hematologic cancers

NEXT ARTICLE

More From BioPortfolio on "Allogene pens $309mm deal with Notch, gaining equity stake and global rights to allogenic therapies for hematologic cancers"

Quick Search

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...